Viridian Therapeutics, Inc.\DE VRDN

What this company does

Its pipeline targets validated pathways and disease-driving mechanisms in autoimmune and rare diseases, including IGF-1R product candidates for thyroid eye disease, FcRn inhibitors for autoimmune disorders, and a TSHR inhibitor program. The company's capabilities span protein and antibody discovery and engineering, biologics manufacturing, nonclinical and clinical development, commercial planning, and commercialization. As of December 31, 2025, the company employed 252 full-time employees located in the U.S., including at its facilities in Waltham, Massachusetts and Boulder, Colorado. Viridian was initially founded as miRagen Therapeutics, Inc., a Delaware limited liability company, in January 2010, and was subsequently incorporated as a Delaware corporation in June 2014. In January 2021, following a merger agreement under which miRagen Therapeutics, Inc. acquired Viridian Therapeutics, Inc., the company changed its name from Miragen Therapeutics, Inc. to Viridian Therapeutics, Inc. Viridian's common stock trades on The Nasdaq Capital Market under the ticker symbol VRDN, and its principal executive office is located in Waltham, Massachusetts.

Written from the business description in Viridian Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.